These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23549020)

  • 1. Leptomeningeal metastasis from prostate cancer.
    Cante D; Franco P; Sciacero P; Girelli G; Casanova Borca V; Pasquino M; Migliaccio F; Tofani S; Grassi L; Marra A; Ozzello F; La Porta MR; Ricardi U
    Tumori; 2013; 99(1):6e-10e. PubMed ID: 23549020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leptomeningeal carcinomatosis in a patient with metastatic prostate cancer: case report and literature review.
    Cone LA; Koochek K; Henager HA; Fausel R; Gade-Andavolu R; Potts BE; Jennings LM
    Surg Neurol; 2006 Apr; 65(4):372-5, discussion 375-6. PubMed ID: 16531199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo large cell neuroendocrine carcinoma of the prostate gland with pelvic lymph node metastasis: a case report with review of literature.
    Okoye E; Choi EK; Divatia M; Miles BJ; Ayala AG; Ro JY
    Int J Clin Exp Pathol; 2014; 7(12):9061-6. PubMed ID: 25674288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined chemoradiation for head and neck region myxofibrosarcoma of the maxillary sinus.
    Cante D; Franco P; Sciacero P; Girelli GF; Casanova Borca V; Pasquino M; Tofani S; Bombaci S; Migliaccio F; Marra A; Numico G; La Porta MR; Ricardi U
    Tumori; 2013; 99(2):e80-3. PubMed ID: 23748836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen in the cerebrospinal fluid: a marker of local disease.
    Orphanos G; Ioannidis G; Michael M; Kitrou G
    Med Oncol; 2009; 26(2):143-6. PubMed ID: 18830829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
    Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leptomeningeal involvement by prostate carcinoma an ominous head of a well-known Hydra.
    Tawadros F; Manthri S; Zayko M; Chakraborty K
    BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31527212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL; Ye DW; Yao XD; Dai B; Zhang SL; Shen YJ; Zhu Y; Zhang W
    Urol Int; 2007; 79(4):307-11. PubMed ID: 18025847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.
    Font A; Murias A; Arroyo FR; Martin C; Areal J; Sanchez JJ; Santiago JA; Constenla M; Saladie JM; Rosell R
    Ann Oncol; 2005 Mar; 16(3):419-24. PubMed ID: 15668260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer.
    Dibiase SJ; Hussain A; Kataria R; Amin P; Bassi S; Dawson N; Kwok Y
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):732-6. PubMed ID: 21036486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study.
    Pan Z; Yang G; He H; Zhao G; Yuan T; Li Y; Shi W; Gao P; Dong L; Li Y
    Int J Cancer; 2016 Oct; 139(8):1864-72. PubMed ID: 27243238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
    Harzstark AL; Rosenberg JE; Weinberg VK; Sharib J; Ryan CJ; Smith DC; Pagliaro LC; Beer TM; Liu G; Small EJ
    Cancer; 2011 Jun; 117(11):2419-25. PubMed ID: 24048789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
    Ross RW; Galsky MD; Febbo P; Barry M; Richie JP; Xie W; Fennessy FM; Bhatt RS; Hayes J; Choueiri TK; Tempany CM; Kantoff PW; Taplin ME; Oh WK
    Cancer; 2012 Oct; 118(19):4777-84. PubMed ID: 22282219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
    Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
    Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approaches to and current treatment of leptomeningeal metastases.
    Chamberlain MC
    Curr Opin Neurol; 1994 Dec; 7(6):492-500. PubMed ID: 7532525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel.
    Kawahara T; Miyoshi Y; Sekiguchi Z; Sano F; Hayashi N; Teranishi J; Misaki H; Noguchi K; Kubota Y; Uemura H
    PLoS One; 2012; 7(10):e48186. PubMed ID: 23118948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
    McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
    Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.